Multicenter phase II trial of interleukin-2, interferon-α, and 13-cis- retinoic acid in patients with metastatic renal-cell carcinoma

Journal of Clinical Oncology

Volumn 16, Issue 5, 1998, Pages 1820-1825

  Stadler, Walter M ^a   Kuzel, Timothy ^a   Dumas, Mary ^a   Vogelzang, Nicholas J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 2; ISOTRETINOIN; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CARDIOMYOPATHY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; FATIGUE; FEMALE; FLU LIKE SYNDROME; HUMAN; HYPERLIPIDEMIA; KIDNEY CARCINOMA; LUNG METASTASIS; MALE; METASTASIS; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

EID: 0031804712     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.5.1820     Document Type: Article

References (23)

1. Parker SL, Tong T, Bolden S, et al: Cancer Statistics, 1997. Ca Cancer J Clin 47:5-27, 1997
2. McDougal WS, Garnick MB: Clinical signs and symptoms of renal cell carcinoma, in Scardino PT, Shipley WU, Vogelzang, NJ, et al (eds): Comprehensive Textbook of Genitourinary Oncology. Baltimore. MD, Williams & Wilkins, 1996, pp 154-159
3. Hawkins MJ: Immunotherapy with high-dose interleukin 2, in Scardino PT, Shipley WU, Vogelzang, NJ, et al (eds): Comprehensive Textbook of Genitourinary Oncology. Baltimore, MD, Williams & Wilkins, 1996, pp 242-247
4. Stadler WM, Vogelzang NJ: Low-dose interleukin-2 in the treatment of metastatic renal cell carcinoma. Semin Oncol. 22:67-73, 1995
5. Parkinson DR, Sznol M: High dose interleukin-2 in the therapy of metastatic renal-cell carcinoma. Semin Oncol. 22: 61-66, 1995
6. Rosenberg SA, Yang SL, Topalian JL, et al: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 271:907-913, 1994
7. Minasian LM, Motzer RJ, Gluck L, et al: Interferon alfa-2a in advanced renal cell carcinoma: Treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 11:1368-1375, 1993
8. Atkins MB, Dutcher JP: Renal-cell carcinoma. N Engl J Med 336:809, 1997 (letter)
9. Yang JC, Topalian SL, Parkinson D, et al: Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: An interim report. J Clin Oncol 12:1572-1576, 1994
10. Vogelzang NJ, Lipton A, Figlin RA: Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: An outpatient multicenter trial. J Clin Oncol. 11:1809-1816, 1993
11. Negrier S, Escudier B, Lasset C, et al: The FNCLLCC CRECY trial: Interleukin 2 + interferon is the optimal treatment to induce responses in metastatic renal cell carcinoma. Proc Amer Soc Clin Oncol 15:629, 1996(abstr)
12. Motzer RJ, Schwartz L, Law TM, et al: Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: Antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol. 13:1950-1957, 1995
13. Berg WJ, Schwartz L, Amsterdam A, et al: Clinical studies of 13-cis-retinoic acid in patients with metastatic renal cell carcinoma. Proc Amer Soc Clin Oncol 16:1162, 1997(abstr)
14. Toma S, Monteghirfo S, Taso P, et al: Antiproliferative and synergistic effect of IFN α-2a, retinoids and their association in established human cancer cell lines. Cancer Lett. 82:209-216, 1994
15. Ilson DH, Motzer RJ, Kradin RL, et al: A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma. J Clin Oncol 10:1124-1130, 1992
16. Elson PJ, Witte RS, Trump DL: Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 48:7310-7313, 1988
17. Lopez-Hanninen E, Kirchner H, Atzpodien J: Interleukin-2-based home therapy of metastatic renal cell carcinoma: Risks and benefits in 215 consecutive single institution patients. J Urol 155:19-25, 1996
18. Mani S, Todd MB, Katz K, et al: Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J Urol 154:35-40, 1995
19. Rini BI, Stadler WM, Spielberger RT, et al: Granulocyte-macrophage colony-stimulating factor (GM-CSF) in metastatic renal cell cancer: Evidence for activity and clinical benefit. Cancer (in press)
20. Kragel AH, Travis WD, Steis RG, et al: Myocarditis or acute myocardial infarction associated with interleukin-2 therapy for cancer. Cancer 66:1513-1516, 1990
21. Schuchter LM, Hendricks CB, Holland KH, et al: Eosinophilic myocarditis associated with high-dose interleukin-2 therapy. Am J Med 88:439-440, 1990
22. Sagaster P, Micksche M, Flamm J, et al: Randomised study using IFN-alfa versus IFN-alfa plus coumarin and cimetidine for treatment of advanced renal cell cancer. Ann Oncol 6:999-1003, 1995.
23. Atkins MB, Sparano J, Fisher RI, et al: Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol 11:661-670, 1993